VIM
ALNY icon

Vinva Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vinva Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.5M Buy
154,972
+118,371
+323% +$35.7M 0.3% 84
2026
Q1 		$11.6M Buy
36,601
+18,640
+104% +$6.34M 0.14% 164
2025
Q4 		$7.14M Buy
17,961
+16,703
+1,328% +$7.39M 0.09% 185
2025
Q3 		$563K Buy
+1,258
New +$512K 0.01% 369

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vinva Investment Management's ALNY Position: Q2 2026 in Review

Vinva Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 323% in Q2 2026, buying an estimated $35.7M and bringing the position to 154,972 shares worth $45.5M. The position accounts for 0.3% of the portfolio, ranked #84.

Vinva Investment Management first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Vinva Investment Management held 154,972 shares of Alnylam Pharmaceuticals worth $45.5M as of Q2 2026.
  • Vinva Investment Management bought 118,371 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $35.7M.
  • Alnylam Pharmaceuticals made up 0.3% of Vinva Investment Management's portfolio in Q2 2026, its #84 holding.
  • Vinva Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vinva Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.